What is Evogene?
Evogene, founded in 1999 and headquartered in Rehovot, Israel, is a computational biology company leveraging advanced AI-driven technological engines, including MicroBoost AI, ChemPass AI, and GeneRator AI. These platforms are designed to accelerate the discovery process for microbes, small molecules, and genetic elements. The company's operational model involves utilizing these proprietary engines through its subsidiaries and strategic partnerships to drive innovation in human therapeutics, ag-chemicals, and large-scale agriculture.
How much funding has Evogene raised?
Evogene has raised a total of $15M across 2 funding rounds:
Stock Offering
$5M
Share Placement
$10M
Stock Issuance/Offering (2013): $5M, investors not publicly disclosed
Share Placement (2020): $10M led by Alpha Capital Anstalt and ARK Investment Management LLC
Key Investors in Evogene
Alpha Capital Anstalt
Alpha Capital Anstalt is an entity that participated in Evogene's 2020 funding round, contributing to the company's strategic investment.
ARK Investment Management LLC
ARK Investment Management LLC, a prominent investment firm, was involved in Evogene's significant capital raise in September 2020, signaling confidence in the company's AI-driven life sciences approach.
What's next for Evogene?
The substantial enterprise-level funding and recent strategic investment indicate Evogene is in a phase of significant scaling and technological advancement. This financial backing is likely to fuel further research and development, expand its AI platform capabilities, and potentially accelerate the commercialization of its life-science based products across its target markets. The company's focus on AI-driven discovery positions it to capitalize on the growing demand for innovative solutions in healthcare and agriculture.
See full Evogene company page
